478
Participants
Start Date
September 15, 2025
Primary Completion Date
December 15, 2027
Study Completion Date
December 15, 2027
PCSK9 inhibitor
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitors are a class of monoclonal antibody drugs that lower low-density lipoprotein cholesterol (LDL-C) by inhibiting the PCSK9 protein, which increases the liver's ability to remove LDL-C from the blood. This intervention involves the use of established PCSK9 inhibitor agents.
Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou
Fujian Medical University Union Hospital, Fuzhou
Dongguan Donghua Hospital, Dongguan
Dongguan People's Hospital, Dongguan
Huadu District People's Hospital of Guangzhou, Guangzhou
Nanfang Hospital of Southern Medical University, Guangzhou
Heyuan People's Hospital, Heyuan
Hengzhou City People's Hospital, Guangxi, Hengzhou
Haikou People's Hospital, Haikou
Hainan Provincial People's Hospital, Haikou
The Second Affiliated Hospital of Hainan Medical University, Haikou
Ganzhou City People's Hospital, Ganzhou
Nanfang Hospital, Southern Medical University
OTHER